Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon
Thumbnail

Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke

All participants were free of ASCVD and had no history of statin use at the start of the study. 

pharmaceutical drug approval process

American Heart Association thinks pharmacists can play a bigger role in AFib care

Pharmacists interact with patients on a regular basis and are seen as a trusted source of health information. Can they help cardiologists improve care for AFib patients? 

Video of James Januzzi explaining the results of a new diabetic cardiomyopathy treatment in ACC 2024 late-breaking ARISE-HF trial. #ACC #ACC24 #ACC2024

Diabetic cardiomyopathy treatment shows promise in ARISE-HF

James Januzzi Jr., MD, said the treatment's overall impact was neutral, but he and his team saw "a very clear and encouraging signal."

Sex, energy drinks and vaccines among the many topics planned for preventive cardiology conference

The three-day event will include sessions about sexual activity among heart patients, depression, energy drinks, stimulants, vaccines and more. The festivities begin Thursday, April 25, in Greece. 

Bayer subsidiary granted FDA’s fast track designation for new congestive heart failure treatment

AskBio, acquired by Bayer for more than $2 billion in 2020, is enrolling patients for a new clinical trial focused on the therapy's effectiveness in adult patients with non-ischemic cardiomyopathy and heart failure. 

pharmaceutical drug approval process

FDA grants fast track designation to new drug for Friedreich's ataxia cardiomyopathy

The new gene therapy candidate is now one step closer to being approved by the FDA. 

PHOTO GALLERY: Highlights from ACC.24 in Atlanta

ACC.24, the American College of Cardiology's annual meeting in Atlanta, featured the latest in cardiovascular research and technologies. Representatives from Cardiovascular Business were there in person to take in the excitement. 

Patient with LVAD

FDA grants anticoagulant its orphan drug designation for treating patients with implanted devices

The anticoagulant was originally developed for patients with end-stage renal disease and atrial fibrillation. 

Displaying 65 - 72 of 297
Design by Adaptive Theme